Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Xihan Wu

Matthias Heinrich Nettekoven

Hasane Ratni

Henner Knust

Jason Christopher Wong

Chungen Liang

Li Chen

Philippe Jablonski

Claus Riemer

Tao Guo

Hongying Yun

Anja Limberg

Lisha Wang

Lichun Feng

Bo Han

Yongfu Liu

Xiufang Zheng

Song Feng

Lu Gao

Jim Zhen Wu

Mengwei Huang

Guozhi Tang

Kenichi Kawasaki

Guy Georges

Caterina Bissantz

Torsten Hoffmann

Alfred Mertens

Walter Vifian

Zhenshan Zhang

A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein Rto R, A, Q, X and Y are as defined in the specification and claims, and their use as a pharmaceutical for the treatment or prophylaxis of respiratory syncytial virus disease.

Compounds for the treatment and prophylaxis of respiratory syncytial virus disease

Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease

The present invention is directed to a compound of formula I, and processes for the manufacture of said compounds as well as medicaments containing said compound. The compounds according to this invention show anti-proliferative and differentiation-inducing activity and are thus useful for the treatment of diseases such as cancer in humans or animals.

Ortho-aminoanilides for the treatment of cancer

The invention relates to a compound of formula I wherein

Pyrrolidine aryl-ether as NK-3 receptor antagonists

The present invention is directed to the compounds of formula wherein Rto Rhave the significances given herein, to processes for the manufacture of said compounds as well as medicaments containing said compounds. The compounds according to this invention show anti-proliferative and differentiation-inducing activity and are thus useful for the treatment of diseases such as cancer in humans or animals.

N-(2-amino-phenyl)-acrylamides

Compounds of formula are HDAC inhibitors. These compounds are useful for the treatment of diseases such as cancer in humans or animals.

Ortho aminoamides for the treatment of cancer

The invention relates to pyrrolidine derivatives of formula wherein

Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists

The invention relates to a compound of general formula wherein are as defined herein or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Pyrrolidine aryl-ether as NK3 receptor antagonists

The present invention relates to a compound of formula I wherein

Piperazine and [1,4]diazepan derivatives as NK antagonists

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Isoquinoline aminopyrazole derivatives

Prolinamide derivatives as NK3 antagonists

Prolinamide-tetrazole derivatives as NK3 receptor antagonists

Growing community of inventors

Shanghai, China

Xihan Wu